{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:10:59Z","timestamp":1789593059043,"version":"build-2803163510"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/grf.0b013e31825caa36","type":"journal-article","created":{"date-parts":[[2012,7,24]],"date-time":"2012-07-24T06:35:00Z","timestamp":1343111700000},"page":"671-680","source":"Crossref","is-referenced-by-count":54,"title":["HPV"],"prefix":"10.1097","volume":"55","author":[{"given":"JON K.","family":"HATHAWAY","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210126","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","article-title":"Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.","volume":"88","author":"Clifford","year":"2003","journal-title":"Br J Cancer"},{"key":"R3-10-20210126","first-page":"447","article-title":"The role of the human papillomavirus in oropharyngeal cancer.","volume":"128","author":"Naidu","year":"2011","journal-title":"Tex Dent J"},{"key":"R4-10-20210126","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1056\/NEJMoa065497","article-title":"Case-control study of human papillomavirus and oropharyngeal cancer.","volume":"356","author":"DSouza","year":"2007","journal-title":"N Engl J Med"},{"key":"R5-10-20210126","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1055-9965.EPI-04-0551","article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.","volume":"14","author":"Kreimer","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R6-10-20210126","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.24116","article-title":"Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis.","volume":"124","author":"De Vuyst","year":"2009","journal-title":"Int J Cancer"},{"issue":"5A","key":"R7-10-20210126","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9343(97)00177-0","article-title":"Epidemiology of genital human papillomavirus infection.","volume":"102","author":"Koutsky","year":"1997","journal-title":"Am J Med"},{"key":"R8-10-20210126","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","article-title":"Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis.","volume":"7","author":"de Sanjose","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"R9-10-20210126","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/oxfordjournals.aje.a010166","article-title":"Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis.","volume":"151","author":"Myers","year":"2000","journal-title":"Am J Epidemiol"},{"key":"R10-10-20210126","doi-asserted-by":"crossref","first-page":"8813","DOI":"10.1158\/0008-5472.CAN-08-1380","article-title":"Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study.","volume":"68","author":"Goodman","year":"2008","journal-title":"Cancer Res"},{"key":"R11-10-20210126","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.vaccine.2004.07.046","article-title":"Efficacy and other milestones for human papillomavirus vaccine introduction.","volume":"23","author":"Pagliusi","year":"2004","journal-title":"Vaccine"},{"key":"R12-10-20210126","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jama.2012.101","article-title":"Prevalence oforal HPV infection in the United States, 2009-2010.","volume":"307","author":"Gillison","year":"2012","journal-title":"JAMA"},{"key":"R13-10-20210126","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1473-3099(09)70108-2","article-title":"Clinicians guide to human papillomavirus immunology: knowns and unknowns.","volume":"9","author":"Einstein","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"R14-10-20210126","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States.","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"key":"R16-10-20210126","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/jnci\/89.12.868","article-title":"Identification of tobacco-specific carcinogen in the cervical mucus of smokers and nonsmokers.","volume":"89","author":"Prokopczyk","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"R18-10-20210126","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00007435-199309000-00007","article-title":"Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon.","volume":"20","author":"Bauer","year":"1993","journal-title":"Sex Transm Dis"},{"key":"R19-10-20210126","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ejca.2009.09.015","article-title":"Cigarette smoking is an independent risk factor for cervical intraepithelial neoplasia in young women: a longitudinal study.","volume":"46","author":"Collins","year":"2010","journal-title":"Eur J Cancer"},{"key":"R20-10-20210126","first-page":"503","article-title":"Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group.","volume":"163","author":"Sellors","year":"2000","journal-title":"CMAJ"},{"key":"R21-10-20210126","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/ije\/dyn033","article-title":"Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys.","volume":"37","author":"Vaccarella","year":"2008","journal-title":"Int J Epidemiol"},{"key":"R22-10-20210126","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0140-6736(07)61684-5","article-title":"Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies.","volume":"370","author":"Appleby","year":"2007","journal-title":"Lancet"},{"key":"R23-10-20210126","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(03)12949-2","article-title":"Cervical cancer and use of hormonal contraceptives: a systematic review.","volume":"361","author":"Smith","year":"2003","journal-title":"Lancet"},{"key":"R24-10-20210126","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ijc.10868","article-title":"Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma.","volume":"103","author":"de Villiers","year":"2003","journal-title":"Int J Cancer"},{"key":"R26-10-20210126","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6111618 L1 virus-like particle (VLP) vaccine.","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"key":"R27-10-20210126","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcv.2011.12.009","article-title":"Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine.","volume":"53","author":"Rowhani-Rahbar","year":"2011","journal-title":"J Clin Virol"},{"key":"R28-10-20210126","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jadohealth.2011.11.004","article-title":"Four-year follow-up of the immunogenicity and safety of the HPV-1618 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.","volume":"50","author":"Schwarz","year":"2012","journal-title":"J Adolesc Health"},{"key":"R29-10-20210126","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"R31-10-20210126","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"R32-10-20210126","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-1618 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"R33-10-20210126","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"R34-10-20210126","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.","volume":"199","author":"Wheeler","year":"2009","journal-title":"J Infect Dis"},{"key":"R36-10-20210126","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6111618 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.","volume":"5","author":"Olsson","year":"2009","journal-title":"Hum Vaccin"},{"key":"R37-10-20210126","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.","volume":"373","author":"Munoz","year":"2009","journal-title":"Lancet"},{"key":"R38-10-20210126","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/annonc\/mdp377","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.","volume":"21","author":"Boss","year":"2010","journal-title":"Ann Oncol"},{"key":"R40-10-20210126","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"key":"R42-10-20210126","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1373\/clinchem.2005.052381","article-title":"Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins.","volume":"51","author":"Waterboer","year":"2005","journal-title":"Clin Chem"},{"key":"R43-10-20210126","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ijc.21897","article-title":"Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).","volume":"119","author":"Mayrand","year":"2006","journal-title":"Int J Cancer"},{"key":"R45-10-20210126","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1086\/517472","article-title":"A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod.","volume":"178","author":"Tyring","year":"1998","journal-title":"J Infect Dis"},{"key":"R46-10-20210126","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijgo.2009.09.012","article-title":"Cryotherapy for HPV clearance in women with biopsy-confirmed cervical low-grade squamous intraepithelial lesions.","volume":"108","author":"Chumworathayi","year":"2010","journal-title":"Int J Gynaecol Obstet"},{"key":"R47-10-20210126","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2559.2007.02956.x","article-title":"Natural history and clearance of HPV after treatment of precancerous cervical lesions.","volume":"52","author":"Aerssens","year":"2008","journal-title":"Histopathology"}],"container-title":["Clinical Obstetrics & Gynecology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003081-201209000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T01:55:27Z","timestamp":1618365327000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003081-201209000-00010"}},"subtitle":["Diagnosis, Prevention, and Treatment"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0b013e31825caa36","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}